Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 3/20 | 0.42 |
| ▸ | HTR1A | P08908 | 11/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4051642 | 0.83 | HTR6 (0.49) | HRH2HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5749127 | 0.82 | CNR1 (0.40) | HTR1ASLC6A2SLC6A4SLC6A3OPRM1 | |
| SCHEMBL5342585 | 0.81 | HRH2 (0.56) | HRH2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4052399 | 0.81 | CFTR (0.42) | HRH2HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4055720 | 0.80 | HRH2 (0.43) | HRH2HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4058326 | 0.79 | HTR2A (0.43) | HRH2HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4058960 | 0.79 | OPRL1 (0.41) | HTR1ASLC6A2SLC6A4SLC6A3OPRM1 | |
| SCHEMBL4058699 | 0.79 | CNR1 (0.55) | HTR1ASLC6A2SLC6A4SLC6A3MAPT | |
| SCHEMBL24567395 | 0.78 | OPRM1 (0.45) | HTR1ASLC6A2SLC6A4SLC6A3OPRM1 | |
| SCHEMBL4053254 | 0.77 | CNR1 (0.47) | HTR1ASLC6A2SLC6A4SLC6A3OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622480-B2 | Selective H1 histamine receptor antagonists; bronchial asthma, allergic rhinitis, conjunctivitis, dermatitis, urticaria and other allergic diseases; e.g. 3-(4-[1-(2-methoxyethyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]piperidin-1-ylmethyl)benzoic acid | LABORATORIOS ALMIRALL S.A. (ES) | 2009-11-24 | — | — | US | disclosed |
| EP-1497292-B1 | AZAINDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | ALMIRALL PRODESFARMA SA (ES) | 2006-06-14 | — | — | EP | disclosed |
| US-20050176751-A1 | Azaindolylpiperidine derivatives as antihistaminic and antiallergic agents | LABORATORIOS ALMIRALL, S.A. (ES) | 2005-08-11 | — | — | US | disclosed |
| EP-1497292-A1 | AZAINDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | Almirall Prodesfarma, S.A. (ES) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003082867-A1 | AZAINDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | ALMIRALL PRODESFARMA S.A. (ES) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176751-A1 | Azaindolylpiperidine derivatives as antihistaminic and antiallergic agents | HRH2, HRH1, HRH4 | HRH2 1/4885HTR1A 56/4885SLC6A2 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.